Standard of Care sensibility: CHOP = yes (30mg/kg)
SUDHL-6 cells
Human SYDHL-6 cells were isolated from the peritoneal effusion of a peritoneal NHL with mixed phenotype (large B-cells and follicular).
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing SUDHL-6 tumours can be treated by intra-peritoneal, intra-venous, intratumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the SUDHL-6 cells as xenograft Mean ± SEM (n=3; take rate 100%)
Antineo can also perform an intra-medullar implantation.
Standard-Of-Care Drug Responses
CHOP, 30 mg/kg, once → Response
Figure 2: ( View PDF)
Effect of CHOP therapy on SUDHL-6 tumour growth Mean ± SEM (n=6 per group; take rate 100%)